Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells
Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells
复制标题
DOI：
10.3109/13813451003631439
复制
发表时间：
2010-05-01
影响因子：
3
通讯作者：
Chantelau, Ernst
中科院分区：
文献类型：
--
作者：
Mayer, Doris;Chantelau, Ernst
背景和目的：甘精胰岛素(Lantus(R))比人胰岛素更能刺激MCF-7细胞的生长。我们研究了服用甘精胰岛素和人胰岛素治疗的糖尿病患者的血清是否表现出类似的效果。方法：对31例C肽阴性的1型糖尿病患者的血清样本进行了研究。以交叉方式，23名患者接受甘精+速效胰岛素类似物治疗，以及类似剂量的人NPH和速效胰岛素治疗。作为对比，8名患者接受了地特胰岛素(Levemir(R))和人NPH的治疗。结果：甘精胰岛素含药血清较人胰岛素含药血清(P<；0.005)促有丝分裂作用增强1.11倍(95%可信区间为1.05~1.18)，地特米含药血清促有丝分裂作用为人含胰岛素血清的0.99倍(95%可信区间0.98~1.02)。
Context and objective: Insulin glargine (Lantus (R)) stimulates growth of MCF-7 cells stronger than human insulin. We investigated if serum from diabetic patients treated with glargine versus human insulin may display a similar effect.Methods: Pairs of serum samples from 31 C-peptide negative type-1 diabetic patients were investigated. In cross-over fashion, 23 patients were treated with glargine plus rapid-acting insulin analogues, and similar doses of human NPH and rapid-acting insulin. For comparison, eight patients were treated with insulin detemir (Levemir (R)) and human NPH. MCF-7 cells were incubated with 10% serum and proliferation was assessed after 72 hours.Results: Serum containing insulin glargine was 1.11(95% CI 1.05-1.18) fold more mitogenic than human insulin-containing serum (p < 0.005); mitogenicity of serum containing detemir was 0.99(95% CI 0.98-1.02) fold that of human insulin-containing serum.Conclusion: The serum of diabetic patients was slightly stronger mitogenic when using glargine as compared to human insulin or detemir for treatment.